CRISPR Therapeutics

139 articles with CRISPR Therapeutics

• Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

  6/11/2021

  Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment.

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - May 25, 2021

  5/25/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in June

• Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

  5/12/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress. Abstract #EP736 entitled “ CTX001 for Sickle Cell Disease: Safety and Efficacy Results from the Ongoing CLIMB SCD-121

• CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer

  5/6/2021

  Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Apr 29, 2021

  4/29/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in May:

• CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

  4/28/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting, to be held in a virtual format from June 4 to 8, 2021.

• CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

  4/27/2021

  Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)

• Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

  4/26/2021

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).

• Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

  4/20/2021

  Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001

• 

  Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics

  4/20/2021

  Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.

• CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

  4/10/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced preclinical data from the Company’s allogeneic chimeric antigen receptor T cell program at the American Association for Cancer Research Annual Meeting 2021.

• CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference

  4/6/2021

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 9:30 a.m. ET.

• CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

  3/10/2021

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.

• CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Mar 03, 2021

  3/3/2021

  CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:

• CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

  2/16/2021

  - More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 - - The first patient treated in the CLIMB-Thal-111 trial completed two years of follow-up and has enrolled in the long-term follow-up trial, CTX001-131 - - Additional data from CTX110™ trial expected to report in 2021, along with top-line data from CTX120™ and CTX130™ -

• CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

  2/5/2021

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET

• 

  BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More

  2/5/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer

  2/1/2021

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Philippe Drouet as Chief Commercial Officer.

• CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

  12/14/2020

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

• CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

  12/5/2020

  The New England Journal of Medicine publishes CTX001 manuscript containing the first report of investigational use of CRISPR/Cas9-based gene editing to treat inherited diseases in humans